SHIM
ADMA icon

Stone House Investment Management’s ADMA Biologics ADMA Stock Holding History

Stone House Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$937 Sell
104
-35
-25% -$552 ﹤0.01% 709
2025
Q4 		$2.54K Buy
139
+130
+1,444% +$2.19K ﹤0.01% 530
2025
Q3 		$132 Buy
+9
New +$154 ﹤0.01% 711

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Stone House Investment Management's ADMA Position: Q1 2026 in Review

Stone House Investment Management reduced its ADMA Biologics (ADMA) stake by 25% in Q1 2026, selling an estimated $552 and leaving 104 shares worth $937. The position accounts for ﹤0.01% of the portfolio, ranked #709.

Stone House Investment Management first reported a position in ADMA in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.54K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Stone House Investment Management held 104 shares of ADMA Biologics worth $937 as of Q1 2026.
  • Stone House Investment Management sold 35 ADMA Biologics shares in Q1 2026, an estimated $552.
  • ADMA Biologics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #709 holding.
  • Stone House Investment Management first reported a position in ADMA Biologics in Q3 2025 and has held it in 3 quarters since.
  • Stone House Investment Management's ADMA Biologics position peaked at $2.54K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.